Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 528,200 shares, a drop of 18.1% from the October 15th total of 644,700 shares. Based on an average trading volume of 159,300 shares, the short-interest ratio is currently 3.3 days. Approximately 2.1% of the company’s shares are short sold.

Hedge Funds Weigh In On Vistagen Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in shares of Vistagen Therapeutics during the first quarter valued at approximately $169,000. Blair William & Co. IL grew its holdings in shares of Vistagen Therapeutics by 29.2% during the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after purchasing an additional 20,000 shares during the period. American Century Companies Inc. boosted its stake in Vistagen Therapeutics by 49.1% during the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock worth $105,000 after buying an additional 9,984 shares during the period. Jane Street Group LLC acquired a new stake in Vistagen Therapeutics in the 3rd quarter valued at approximately $59,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Vistagen Therapeutics in the third quarter valued at $64,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Trading Down 3.7 %

NASDAQ:VTGN opened at $2.63 on Friday. The company has a market capitalization of $73.22 million, a P/E ratio of -2.12 and a beta of 0.78. The firm has a fifty day simple moving average of $3.04 and a 200-day simple moving average of $3.49. Vistagen Therapeutics has a 12 month low of $2.58 and a 12 month high of $5.86.

Analysts Set New Price Targets

Separately, William Blair upgraded Vistagen Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.